History
2023: Vaccine Patch Plant Launch
In mid-June 2023, biotech company Vaxxas opened a needle-free vaccine patch plant in Brisbane, Australia.
The enterprise with an area of 5.5 thousand square meters. m. Will produce vaccine patches for clinical trials at late stages and the first commercial products. The company employs 130 people, it also serves as the headquarters of Vaxxas. From 2026 to 2028, the company expects the number of employees at the plant to grow to 200.
The Brisbane facility consists of two independent aseptic cleanrooms. The space in the plant meets the requirements of good manufacturing practice, and production areas for medical devices in Australia. The plant also includes a clean room for assembling devices and supporting infrastructure such as office space and laboratories.
The joint facility, funded by the Queensland government and Vaxxas, will produce millions of high density microchips (HD-MAP) per year. The HD-MAP technology platform from Vaxxas uses an array of ultra-high density projections applied to the skin in the form of a patch through a small applicator device. When applied to the skin, the patch delivers the vaccine to immune cells located under the surface of the skin.
Vaxxas CEO David Hoey spoke about how this facility will significantly increase our production capacity, create new local skilled jobs and enable Vaxxas to conduct late-stage clinical trials that will bring our first commercial vaccine products to market. The Brisbane City Biomedical Centre will firmly take Australia's place at the forefront of vaccine technology innovation.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |